Lombard Odier Asset Management (USA)’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-60,000
Closed -$3.74M 338
2021
Q4
$3.74M Sell
60,000
-37,000
-38% -$2.17M 0.15% 80
2021
Q3
$5.74M Buy
+97,000
New +$6.39M 0.25% 60
2021
Q1
Sell
-20,000
Closed -$1.24M 316
2020
Q4
$1.24M Buy
+20,000
New +$1.23M 0.06% 188
2014
Q2
Sell
-425,000
Closed -$22.1M 196
2014
Q1
$22.1M Buy
425,000
+175,000
+70% +$9.31M 0.85% 38
2013
Q4
$13.3M Sell
250,000
-50,000
-17% -$2.55M 0.57% 68
2013
Q3
$13.9M Buy
300,000
+25,000
+9% +$1.1M 0.7% 45
2013
Q2
$12.3M Buy
+275,000
New +$11.9M 0.69% 56

Other funds holding BMY

Lombard Odier Asset Management (USA)'s BMY Position: Q1 2022 in Review

Lombard Odier Asset Management (USA) sold out of Bristol-Myers Squibb (BMY) in Q1 2022, closing a stake of 60,000 shares — an estimated $3.74M sold.

Lombard Odier Asset Management (USA) first reported a position in BMY in Q2 2013 and held it in 7 quarters. The position peaked at $22.1M in Q1 2014. 2,516 funds tracked by Wall St. Rank hold BMY as of Q1 2022.

  • Lombard Odier Asset Management (USA) reported no remaining Bristol-Myers Squibb position as of Q1 2022 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 60,000 Bristol-Myers Squibb shares in Q1 2022, an estimated $3.74M.
  • Lombard Odier Asset Management (USA) first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 7 quarters.
  • Lombard Odier Asset Management (USA)'s Bristol-Myers Squibb position peaked at $22.1M in Q1 2014.
  • 2,516 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2022.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q1 2022, filed 16 May 2022.